The biotech company has the option to market new vaccines based on a patented invention, while the research group responsible for the invention gains access to the company’s technology and facilities for the manufacturing of vaccines for humans and the carrying out of clinical trial phases.
That is the essence of a newly made deal between University of Copenhagen and the swizz-based biotech company Okairos.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app